Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVHIC003: Controlled Human Infection Model for SARS-CoV-2 Omicron EG.5.1
NCT07397455Phase 1Recruiting
- Sponsor
- Imperial College London
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Imperial College London. Primary endpoints: Safety and human clinical response to intranasal challenge at 28 days and Selection of the SARS-CoV-2 Omicron EG.5.1 dose(s) required to induce laboratory confirmed upper respiratory tract infection at 10 days. Started Jul 2026; status: recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07397455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07397455.